Patients undertaking maintenance haemodialysis may develop a variety of neurological disorders, the most serious of which is aluminium induced encephalopathy. Abnormally raised serum concentrations of pterins are found in dialysis patients, and neonates with tetrahydrobiopterin deficiency develop mental dysfunction. Dihydropteridine reductase, essential for maintenance of normal levels of tetrahydrobiopterin, is inhibited when aluminium is added to brain homogenate at similar concentrations to those found in aluminium encephalopathy. We have previously shown that erythrocyte dihydropteridine reductase activity was reduced in non-encephalopathic dialysis patients and inversely related to serum aluminium concentration. Concentrations of serum biopterin derivatives were raised but not related to either aluminium or dihydropteridine reductase.
Introduction
Ever since maintenance haemodialysis became a practical and successful form of renal replacement therapy, neurological disorders have complicated its use. The increased incidence of atherosclerosis may lead to cerebrovascular disease; uraemic toxins cause periph-\\·as discovered to be caused by aluminium in 1976 \\hen abnormally high levels of the element were found in brain studied at post mortem (2) . The sources of aluminium were identified as contaminated water used to prepare dialysate, and oral aluminium containing phosphate binders used to control hyperphosphataemia.
As a result there has been much interest in neurotransmitter metabolism in uraemic patients. The first reports suggesting impaired neurotransmitter metabolism in such patients related to the pterins. The synthesis of the neurotransmitters tyrosine, dopa , noradrenaline and 5-hydroxytryptophan is dependent on hydroxylation which in turn is dependent on the cofactor tetrahydrobiopterin. Normal levels of tetrahydrobiopterin are maintai ned principally by a regenerative pathway from dihydrobiopterin, but also by its slow synthesis from guanosine triphosphate (Fig. 1) . Three hyperphenylalaninaemic clinical syndromes associated with enzyme deficiency have been identified: Type I (or classical phenylketonuria) due to deficiency of phenylalanine hydroxylase; Type II associated with dihydropteridine reductase (DHPR) deficiency; a nd Type III due to defective synthesis of tetrahydrobiopterin (3 -6) (Fig. 1 ).
These conditions can be differentiated by assaying the relevant pterins and enzymes. In Type II hyperphenylalaninaemia elevation of serum or whole blood biopterin, with normal neopterin, indicates deficient conversion of dihydrobiopterin to tetrahydrobiopterin by DHPR (which itself can be measured in erythrocytes). The neopterin/ biopterin ratio is therefore reduced. Normal or low biopterin and raised neopterin concentrations with normal DHPR activity suggests Type III hyperphenylalaninaemia .
Altmann eT at.: Pterin meta bolism in haemodialysis patients Baker et al. and Leeming el al. found abnormal concentrations of biopterins in the serum and urine of patients with chronic renal failure (7, 8) . Leeming found high levels of biopterin derivatives in their blood, but low urinary levels, concluding that the kidney must participate in their elimination. Dhondt confirmed these findings and reported elevated levels of serum neopterin in renal failure (9) . Other neurotransmitters have a lso been studied: Sullivan reported increased levels of tryptophan in cerebrospina l fluid and plasma (10) ; several studies have reported reduced levels of y-aminobutyric acid and choline acetyl-transferase in CSF and brains of uraemic patients (11, 12) . Furthermore, plasma phenylalanine concentrations are raised (13) , possibly due to the disorder in pterin metabolism.
Following the identification of aluminium as the cause of dialysis dementia, the condition rapidly declined in incidence due to reduction in dialysate aluminium content and to the more cautious use of aluminium containing phosphate binders. However, the possibility remained that mild cerebral damage might still result from the treatment, which in practice is a lways associated with a positive aluminium balance. In 1979 Leeming and Blair reported that if rat brain homogenate was exposed to aluminium in concentrations similar to those found in the brains of patients dying with aluminium encephalopathy the activity of dihydropteridine reductase in it was inhibited by 40 % (14) . This effect was later confirmed by Dhondt in the hamster (15) . Because erythrocyte DHPR activity is used as a measure of brain DHPR in the diagnosis of primary hyperphenylalaninaemias, we investigated erythrocyte DHPR in long-term haemodial ysis patients without overt encephalopathy, who had been exposed to relatively small quantities of aluminium. Erythrocyte DHPR activity is related to the haemoglobin concentration and is consequently expressed in terms of this. However, as dialysis patients are often severely anaemic, we felt it was necessary to determine whether this correction was by itself adequate, or whether anaemia per se altered the co-enzyme's activity. Blood was serially diluted from a haemoglobin of 14.8 to 3.0 gl dl and erythrocyte DHPR activity (in units per mg Hb) was found to be inversely related to haemoglobin concentration (r = 0.99, P < 0.001) according to the linear equation, DHPR = 3.54 -(0 .1 x haemoglobin).
In our patients, erythrocyte DHPR activity was inhibited and was inversely related to their serum aluminium concentration (r = -0.61, P < 0.001). This could not be accounted for by their anaemia, and DHPR was less than that predicted from their haemoglobin concentration in those patients whose serum aluminium exceeded the modest value of 55 jlg/l (16) . A single intravenous infusion of desferrioxamine (an aluminium chelator) caused a significant rise in DHPR activity, possibly due to removal of aluminium from tissue binding sites. Our postulate that aluminium inhibited brain as well as erythrocyte DHPR was supported by the separate finding that in 4 dialysis patients who died without encephalopathy, brain DHPR activity was inversely related to their serum aluminium, although the small numbers precluded proper statistical analysis (17) .
We also noted that concentrations of serum biopterin derivatives, measured with the Crithidia fasciculata method, were markedly elevated in our patients, consistent with an accumulation of dihydrobiopterin resulting from DHPR inhibition (16) . However they did not correlate with serum aluminium or erythrocyte DHPR (r = 0.28 , ns), and we postulated that other factors, such as renal failure itself and leukocyte activation by dialysis membranes, might have influenced their serum pterin concentrations (16, 18) .
Pterins have functions other than those relating to neurotransmitter synthesis. In 1982 it was reported that pteridines were secreted by activated lymphocytes (19, 20) and a year later that serum and urinary neopterin concentrations rose prior to renal graft rejection, due to increased production by activated T cells (21 -25) . Further studies from Huber, in 1984, confirmed more specifically that y-interferon-activated macrophages secrete neopterin (26) , although it is possible that other activated T-cells also produce it. In 1986, Woloszczuk reported that during graft rejection serum levels of y-interferon correlate very well with serum neopterin levels (27) . It appears that 113 neopterin is the only pterin produced by the activated macrophage and, although the exact role of pterin metabolism in the cell is not fully understood, it has been suggested that it is essential for the production of cytotoxins (28) .
Leucocytes and complement may be activated by dialysis membranes (29, 30) and Craddock reported that the often profound hypoxia experienced by patients whilst undergoing haemodialysis arises, in some cases, from the pulmonary sequestration of activated white blood cells (31) . Other causes of dialysis induced leucocyte activation include macrophage activation by silicone from the blood tubing, resulting in liver granulomata (32).
Both biopterin and neopterin are excreted by the kidneys, and in patients with renal failure their concentrations correlate well with serum creatinine concentrations (25, 33) . During haemodialysis blood biopterin and neopterin concentrations fall because they are dialysable, but they remain above normal (9).
These factors: impaired renal excretion, removal by dialysis, and production by activated T cells, all potentially influence the serum biopterin concentrations found in haemodialysis patients, and would mitigate against any simple relationship between biopterins and their erythrocyte DHPR or measures of aluminium exposure. Serum neopterin might be high, normal or low, depending on the interactions between these factors.
To investigate this further we have measured erythrocyte DHPR activity, serum neopterin and biopterin concentrations, and related them to indices of aluminium exposure in non-encephalopathic haemodialysis patients. Serum biopterin and neopterin concentrations were corrected for their excretion rate using the serum creatinine as the correction factor.
Patients and Methods
Seventeen otherwise fit regular haemodialysis patients, none of whom had any overt signs of encephalopathy, were studied. Eight of these had previously been investigated for erythrocyte DHPR inhibition, and accurate information on aluminium exposure was available in ten: this included cumulative dialysate aluminium, cumulative oral aluminium intake from phosphate binders, bone aluminium content, and the rise in serum aluminium following a single intravenous infusion of desferrioxamine. All blood samples were taken pre-dialysis.
Aluminium assay
A Varian AA1275 atomic absorption spectrophotometer and GTA95 electrothermal atomizer were used for the estimation of aluminium in blood and in bone samples obtained by iliac crest bone biopsy (34) . All appliances used in the assay were confirmed free from aluminium contamination. Quantification of aluminium exposure has been described elsewhere (35) . Concentrations in normal subjects' serum are less than 10 ~g/l.
Creatinine
Serum creatinine was assayed using an autoanalyser (Technicon SMAC) and urine creatinine with a Technicon AA2 single channel analyzer (36) . Other haematological and biochemical measurements were performed by standard laboratory techniques.
Dihy dropteridine reductase activity
DHPR activity was assayed by the method of Narisawa as previously described (16, 37) .
Biopterin and Neopterin
Serum biopterin and neopterin were measured by HPLC according to the method of Fukushima and Nixon (38) . The results are expressed in ~g/l and also after correction for serum creatinine concentration, then being expressed as ~g/mg creatinine. Control subjects were drawn from staff members.
Statistical methods
The data are expressed as mean ± SEM and ranges where appropriate. The significance of the differences between paired or unpaired data was assessed by Student's test. Correlations were assessed (after log transformation where appropriate) by linear regression analysis (39) . Two-tailed values of P < 0.05 were regarded as significant. (Table 1) and, in patients, neither were correlated with serum creatmme (r = 0.36 and r = 0.13 respectively). There was no correlation between neopterin and biopterin (Fig. 2a) , although if they were corrected for serum creatinine concentration a weak relationship between them could be demonstrated (Fig. 2b) . Table 1 . Serum neopterin and biopterin concentrations in dialysis patients and controls.
Controls (n = 7)
Patients (n = 17) There was no relationship between any of the indices of aluminium exposure and either corrected or uncorrected neopterin concentrations, or the neopterin/ biopterin ratio. However there was a weak correlation between corrected (but not uncorrected) serum biopterin and bone aluminium concentration, this being the best index of body aluminium content (Fig. 3a, b) .
Neopterin, biopterin and DHPR
In previous studies (16) serum biopterin derivatives (measured by the Crithidia method) were not related to erythrocyte DHPR activity (Fig. 4) . In this study, however, there was a striking inverse relationship bctween corrected biopterin concentrations and DHPR activity (r = -0.986, P = 0.0001), to which uncorrected biopterin was much less closely related (Fig.  5a, b) . Neither neopterin concentrations (whether corrected or uncorrected) (Fig. 6a, b) nor neopterin/biopterin ratios were related to erythrocyte DHPR activity (r = 0.1 , P = 0.7). Biopterin derivatives (~g/l) Figure 4 . Lack of relationship between concentrations of serum biopterin derivatives a nd erythrocyte DHPR activity. Se rum ncoptl'rin (p g/m g c reatinine) Figure 6 . There was no relationship between either unco rrected (a) or creatinine corrected se rum neopterin concentration (b) and erythrocyte DHPR activity (log scales).
Discussion
We have reported previously that raised concentrations of serum biopterin derivatives in haemodialysis patients with only modestly raised serum aluminium concentrations did not correlate with either erythrocyte DHPR activity or serum aluminium concentrations . In this study we measured biopterin and neopterin concentrations by HPLC. Biopterin concentrations correlated inversely with DHPR activity whilst neopterin concentrations did not correlate. Although pre-dialysis serum creatinine may be regarded as a relatively crude index of both residual renal function and efficacy of dialysis, we have demonstrated a much closer inverse relationship between erythrocyte DHPR and serum biopterin after this has been corrected for pre-dialysis serum creatinine. Thus, the relationship between corrected biopterin and bone aluminium content, and our previous finding of an inverse correlation between erythrocyte DHPR and serum aluminium, suggest that aluminium can cause changes in pterin, and possibly neurotransmitter, metabolism which are analogous to those found in Type II hyperphenylalaninaemia.
In contrast, we were unable to demonstrate any relationship between serum neopterin (corrected or uncorrected) and erythrocyte DHPR or any index of aluminium exposure, and only a weak correlation between corrected biopterin and neopterin values. This supports the possibility that factors other than impa ired elimination through native kidneys and dialyser affect serum neopterin in haemodialysis patients.
Relative to their concentration in normal subjects, concentrations of neopterin were much higher than those of biopterin in haemodialysis patients, suggesting increased production of neopterin. Previous in vitro studies have suggested that activated macrophages secrete neopterin, but not biopterin . This has been considered due to activation, by y-interferon, of dihydroneopterin synthesis from guanosine triphosphate. It has been postulated that this, in turn, could be converted to tetrahydroneopterin, necessary for the production of 3-hydroxy-anthranilic acid essential for macrophage cytotoxicity (28) . Our findings are compatible with the suggestion that in haemodialysis patients macrophage activation, known to be induced by contact with dia lysis membranes, may cause release of neopterin and, thereby, inferfere with the expected relationship between neopterin and biopterin. In addition, aluminium may inhibit the conversion of dihydroneopterin triphosphate to tetrahydrobiopterin, which would lead to a rise in serum neopterin concentrations. The serum neopterinjbiopterin ratio would, therefore, no longer be a valid expression of tetrahydrobiopterin metabolism in haemodialysis patients.
Our results provide further evidence for an adverse effect of aluminium on pterin metabolism, and adds further weight to the suggestion that dialysis patients' aluminium exposure should be as low as possible.
